UNITE: biomarkers of response to enfortumab vedotin in patients with advanced urothelial carcinoma

Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE StudyПодробнее

UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

UNITE: investigating biomarkers of response to enfortumab vedotin in patients with advanced UCПодробнее

Biomarkers of TRAEs in Patients With Advanced UC Treated With EV: Analysis of the UNITE StudyПодробнее

Molecular markers guiding treatment approaches in bladder cancerПодробнее

EV-201, EV-301 and UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

UNITE: efficacy of enfortumab vedotin in advanced urothelial cancerПодробнее

Rationale + study design of UNITE: biomarkers of response to enfortumab vedotin in advanced UCПодробнее

UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

Sequencing ADCs and finding novel biomarkers for urothelial carcinomaПодробнее

The role of enfortumab vedotin in earlier lines and stages of urothelial cancer | Arjun BalarПодробнее

NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial CarcinomaПодробнее

EV-201: enfortumab vedotin for bladder cancerПодробнее

EV-302: 1L enfortumab vedotin in combination with pembrolizumabПодробнее

EV-201: Enfortumab an option for cisplatin-ineligible advanced UC | Arjun BalarПодробнее

EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBCПодробнее

EV-301: Enfortumab vedotin boosts advanced urothelial cancer survival | Thomas PowlesПодробнее

Enfortumab vedotin in urothelial cancerПодробнее

EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancerПодробнее